Daniel GoldmanSell
ENTA · Transaction Jul 12, 2023 · Filed Aug 13, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · ENTA
+2.59% · +$0.3400 · Vol 335.2K
Market closed · last close 4:00 PM ET · price as of 16:04:45 ET
Enanta Pharmaceuticals Inc
Biotechnology
$13.47
Veridion Score
BETAMEDIUM CONF · 5/6 factorsFri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET · ENTA
MethodologySentiment absence reason unknown
ENTA
Enanta Pharmaceuticals Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
NEUTRAL
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
54/ 100
Veridion Score
NEUTRAL · MEDIUM confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is ENTA moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Enanta Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
2013
Employees
120
Country
US
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$13.27
Day high
$13.70
Day low
$13.09
Previous close
$13.13
52W high
$16.85
-20.06% from high
52W low
$7.17
65% of range
Market cap
$392.3M
EPS
$-2.6000
Beta
0.20
Shares out
29.1M
Volume
335.2K
1.93× rel vol
Avg volume
173.7K
VWAP
$13.43
Price history computed in-house
1W
+4.99%
1M
+5.40%
3M
-0.44%
1Y
+52.55%
YTD
-14.58%
SMA 50 $13.34 · above
SMA 200 $13.49 · below
52W position 65%
ENTA overview
Related filings and maps
Public disclosures
Congress activity in ENTA
Official filing ↗
Enanta Pharmaceuticals, Inc. · Transaction May 27, 2015 · Filed Jun 7, 2015 · $1,001 to $15,000
Enanta Pharmaceuticals, Inc. · Transaction Mar 20, 2015 · Filed Apr 11, 2015 · $1,001 to $15,000
Federal contracts
ENTA contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ENTA in this window.
Lobbying spend
ENTA lobbying filings, year to date.
Registered lobbying filings matched to Enanta Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ENTA in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for ENTA.
Options
Sovereign unlock shows live options positioning for ENTA.